These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38433053)

  • 1. [Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor].
    Jia C; Yao XF; Zhang M; Guan XX; Wang JW; Song HC; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):257-263. PubMed ID: 38433053
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
    Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
    Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
    Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
    Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
    Fawzy M; Bahanassy A; Samir A; Hafez H
    Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
    Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
    Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
    Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
    Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
    Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
    Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
    Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children.
    Loke BN; Wong MK; Tawng KD; Kuick CH; Jain S; Lian D; Wagner E; Zou Y; Ganesan V; Sim SW; Lee YT; Chin F; Chan MY; Tan AM; Teh BT; Soh SY; Chang KTE; Loh AHP
    Int J Cancer; 2019 Mar; 144(6):1234-1242. PubMed ID: 30362502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemizygous deletions of chromosome band 16q24 in Wilms tumor: detection by fluorescence in situ hybridization.
    Shearer PD; Valentine MB; Grundy P; DeCou JM; Banavali SD; Komuro H; Green DM; Beckwith JB; Look AT
    Cancer Genet Cytogenet; 1999 Dec; 115(2):100-5. PubMed ID: 10598141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology.
    Spreafico F; Gamba B; Mariani L; Collini P; D'Angelo P; Pession A; Di Cataldo A; Indolfi P; Nantron M; Terenziani M; Morosi C; Radice P; Perotti D;
    J Urol; 2013 Jan; 189(1):260-6. PubMed ID: 23174227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copy Number Variations in Wilms Tumor: A Pilot Study From India.
    Rahiman EA; Singh M; Bhatia P; Kakkar N; Trehan A; Bansal D
    J Pediatr Hematol Oncol; 2020 Jul; 42(5):e299-e304. PubMed ID: 31851072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
    Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
    J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.